Next-Generation aGile trial targets glioblastoma, personalizing treatments with participants' DNA.

Researchers have launched a pioneering trial designed to transform brain cancer treatment, specifically targeting glioblastoma. The "next-Generation aGile Genomically Guided Glioma platform trial" will use participants’ DNA to tailor treatments based on their genetic profiles. Funded by Cancer Research UK and Minderoo Foundation, the trial will allow for rapid testing of various drugs, including those developed for other cancers, marking a significant advancement in brain cancer therapy.

October 23, 2024
4 Articles

Further Reading